Search

OPKO Health Inc

Закрыт

СекторЗдравоохранение

1.36

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

1.35

Макс.

1.38

Ключевые показатели

By Trading Economics

Доход

46M

-8.4M

Продажи

39M

164M

Прибыль на акцию

-0.01

Рентабельность продаж

-5.145

Сотрудники

2,275

EBITDA

40M

12M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+120.59% upside

Дивиденды

By Acuity

Следующий отчет о доходах

28 окт. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

131M

1B

Предыдущая цена открытия

1.36

Предыдущая цена закрытия

1.36

Новостные настроения

By Acuity

50%

50%

154 / 340 Рейтинг в Healthcare

OPKO Health Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

17 авг. 2026 г., 19:06 UTC

News

OPKO Health Inc. shares are lower today, continuing a decline since Friday. The company issued $125 million in senior secured notes linked to mazdutide royalties.

14 авг. 2026 г., 19:36 UTC

OPKO Health Inc shares are lower amid broader market concerns following a reported decline in retail sales for July. The stock reached a session low earlier.

13 авг. 2026 г., 23:01 UTC

OPKO Health shares lower in after-market trading, declining since Thursday's close amid mixed macroeconomic signals and uncertainty in the market.

12 авг. 2026 г., 19:36 UTC

OPKO Health Inc shares are modestly higher, reflecting a positive market environment amid recent risk asset gains. Core CPI data aligns with forecasts, supporting steady interest rates.

11 авг. 2026 г., 19:36 UTC

OPKO Health Inc shares are higher, maintaining a position above their 20-day moving average amid broader market sentiment influenced by geopolitical tensions and inflation reports.

10 авг. 2026 г., 19:46 UTC

OPKO Health Inc. shares are trading higher amid broader market uncertainty, reflecting notable strength above its 20-day moving average since Friday's close.

7 авг. 2026 г., 23:01 UTC

OPKO Health shares advanced in after-market trading, recovering from earlier losses amid broader market dynamics and a slight decline in the unemployment rate.

6 авг. 2026 г., 19:16 UTC

OPKO Health Inc. shares are lower today amid notable volatility, with economic data showing initial jobless claims rose slightly ahead of tomorrow's non-farm payrolls report.

5 авг. 2026 г., 23:01 UTC

OPKO Health shares are lower in after-market hours, reflecting broader market weakness amid recent economic data showing weaker-than-expected U.S. job growth.

4 авг. 2026 г., 23:06 UTC

OPKO Health Inc. shares are higher in after-market trading, settling with a cumulative gain following a brief dip at the session's start.

3 авг. 2026 г., 23:01 UTC

OPKO Health Inc shares increased in after-market trading, maintaining a steady rise since Monday's close amid a generally positive market backdrop.

31 июл. 2026 г., 19:45 UTC

OPKO Health Inc. shares are trading roughly flat today, hovering around the middle of their one-month range and above the 20-day moving average.

30 июл. 2026 г., 23:11 UTC

OPKO Health Inc. shares are lower in after-market hours, continuing a recent trend amid broader market uncertainty following the Federal Reserve's interest rate decision.

29 июл. 2026 г., 23:46 UTC

No specific news was identified for OPKO Health Inc. Shares remained roughly flat during after-market hours, trading near unchanged since Wednesday's close.

28 июл. 2026 г., 23:41 UTC

News

OPKO Health reported a narrowed net loss of $8.4 million and raised revenue guidance, but shares are lower in after-market hours following recent gains.

27 июл. 2026 г., 23:41 UTC

News

OPKO Health reported second-quarter revenues of $163.5 million, surpassing expectations. The company also raised its full-year sales guidance, boosting shares in after-market trading.

24 июл. 2026 г., 22:06 UTC

OPKO Health Inc shares are higher in after-market trading, reaching a peak shortly after the market closed. No specific news was identified for this movement.

22 июл. 2026 г., 18:31 UTC

OPKO Health is declining today, having pulled back from earlier gains amid broader market volatility and rising geopolitical tensions.

21 июл. 2026 г., 22:56 UTC

No specific news was identified for OPKO Health during after-market hours. The stock remains roughly flat, positioned 12.60% below its 20-day moving average.

20 июл. 2026 г., 19:51 UTC

OPKO Health Inc shares are higher in Monday's session, reflecting positive trading conditions. Broader market dynamics are supported by strength in Asian markets.

Сравнение c конкурентами

Изменение цены

OPKO Health Inc Прогноз

Целевая цена

By TipRanks

120.59% рост

Прогноз на 12 месяцев

Средняя 3 USD  120.59%

Максимум 3 USD

Минимум 3 USD

Основано на мнении 3 аналитиков Wall Street, спрогнозировавших целевые цены для OPKO Health Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

3 ratings

2

Покупка

1

Удержание

0

Продажа

Настроения

By Acuity

154 / 340Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании OPKO Health Inc

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 2007 and is headquartered in Miami, Florida.
help-icon Live chat